Clinical effect of ambroxol hydrochloride solution for inhalation combined with montelukast sodiumH chewable tablets in the treatment of pediatric asthmatic bronchopneumonia
Objective To observe the clinical effect of ambroxol hydrochloride solution for inhalation combined with montelukast sodium chewable tablets in the treatment of pediatric asthmatic bronchopneumonia.Methods Sixty cases of children with pediatric asthmatic bronchopneumonia received by Pingxiang Maternity and Child Care from August 2021 to October 2022 were selected,and they were divided into observation group and control group using the random number table method,with 30 cases in each group.The control group was given budesonide,terbutaline nebulized inhalation and other conventional treatment,and the observation group was treated with ambroxol hydrochloride solution for inhalation combined with montelukast sodium chewable tablets on the basis of the control group,and the two groups were treated for 7 days.The treatment effect,clinical symptom improvement time,hospitalization time,white blood cell count,neutrophil count,the levels of CRP before and after treatment,and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 100.00％,which was higher than that of 76.67％in the control group(x2=7.925,P=0.005).The time of improvement of wheezing,rales,cough,fever and hospitalization in the observation group were shorter than those in the control group(P＜0.01).After 7 days of treatment,the levels of white blood cell count,neutrophil count,and CRP of the two groups were lower than those before treatment,and the observation group was lower than that of the control group(P＜0.01).There was no statistically significant difference in the total incidence of adverse reactions between the observation group and control group(3.33％vs.6.67％,P=1.000).Conclusion The efficacy of ambroxol hydrochloride solution for inhalation combined with montelukast sodium chewable tablets in the treatment of pediatric asthmatic bronchopneu-monia is remarkable,which can shorten the recovery time of the children,improve the level of inflammatory indexes,and has a high degree of safety.
万方数据
维普
